Bioretec Oy Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Alan Donze

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	1.7yrs

Recente managementupdates

Recent updates

CEO

Alan Donze (59 yo)

less than a year

Tenure

Mr. Alan Donze is Chief Executive Officer of Bioretec Oy from May 20, 2024. Mr. Donze has held senior leadership positions for a number of other medical device and technology companies including Smith Neph...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alan Donze	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Johanna Salko	Chief Financial Officer	3.8yrs	geen gegevens	geen gegevens
Esa Hallinen	Director of Operations	1.3yrs	geen gegevens	geen gegevens
Timo Lehtonen	Chief Technology Officer	less than a year	geen gegevens	geen gegevens
Rami Ojala	Sales & Marketing Director	2.8yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BRETEC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tomi Numminen	Chairman of the Board	8.5yrs	geen gegevens	geen gegevens
Kustaa Poutiainen	Director	1.5yrs	geen gegevens	geen gegevens
Sarah Van Hellenberg Hubar-Fisher	Director	3.6yrs	geen gegevens	geen gegevens
Michael Piccirillo	Director	6.8yrs	geen gegevens	geen gegevens
Paivi Malinen	Director	2.6yrs	geen gegevens	geen gegevens
Klaus Dresing	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Fan Liu	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Theddy Slongo	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Wang	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Richard Assaker	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Stefan Rammelt	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Verena Schreiber	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BRETEC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw bestuur.

Bioretec Oy Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd Announces CEO Changes

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Recent updates

Bioretec Oy has filed a Follow-on Equity Offering in the amount of €5 million.

Bioretec Ltd. Updates Its Product Development Strategy by Accelerating the Product Development of RemeOs™? Spinal Interbody Cage

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Ltd. Reports Successful Clinical Outcomes from U.S. Controlled Launch of RemeOs Trauma Screw

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition

Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage

New minor risk - Share price stability

Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation

Bioretec Oy to Report Q2, 2024 Results on Aug 15, 2024

Bioretec Ltd Announces CEO Changes

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor

Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws

Bioretec Oy to Report First Half, 2023 Results on Aug 11, 2023

No independent directors

Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023

Bioretec's Hybrid Composite Patent Has Been Approved in Europe

Bioretec Oy Announces ActivaPin Bioresorbable Implant Provides Good Alternative Treatment of Pediatric Elbow Injuries

Bioretec Ltd Announces Bioresorbable Activa IM-Nail™ Shows Convincing Results in Post-Market Clinical Follow Up Study for the Treatment of Children's Forearm Fractures

Bioretec Ltd Submits Market Authorization Request for Its Bioresorbable RemeOs™ Magnesium Screw in the U.S

No independent directors

Bioretec's ActivaPin(TM) Bioresorbable Implant Provides Excellent Clinical Outcome in the Treatment of Pediatric Wrist Fractures

Bioretec Oy Announces Appointment of Päivi Malinen as Member of the Board of Directors

Bioretec Oy has completed an IPO in the amount of €1.74 million.

No independent directors

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd